Quidel Polyclonal Antiserum to SC5b-9 Protein (Neoepitope)
貨號
A317
規格
0.25 mL
形式
Whole antiserum
防腐劑
≤ 0.1% Sodium Azide
物種交叉反應
Species cross reactivity not tested
儲存
2°C to 8°C (≤ 30 days)
For long-term storage (> 30 days), aliquot and store at ≤ –20°C. Avoid repeated freeze-thaw.
使用說明
For Research Use Only. Not for use in diagnostic procedures
產品描述
Highly purified SC5b-9 was isolated and used to immunize rabbits. The Anti-Human SC5b-9 Neoantigen IgG
fraction is stringently absorbed with normal complement proteins to be monospecific for the SC5b-9 neoantigen.
The purified IgG Fraction was tested by immunodiffusion and determined to be monospecific for the SC5b-9
neoantigen。 Quidel Polyclonal Antiserum to SC5b-9 Protein (Neoepitope)
背景
Activation of the terminal complement pathway is the result of activation of any of the three pathways in the
complement system: the classical, alternative and lectin pathways. In this process, complement protein C5 is
cleaved to C5b and may then interact sequentially with complement proteins C6, C7, C8 and C9 forming the
terminal complement complex (TCC). In the presence of a membrane, these complexes can form transmembrane
pores causing complement mediated cytolysis. In the absence of a target membrane, the TCC binds to naturally
occurring regulatory serum proteins and the resulting products are commonly called SC5b-9.
應用
Applications of the Anti-Human SC5b-9 Neoantigen IgG Fraction have been evaluated, and include immunodiffusion
and ELISA. Testing by Western Blot is not recommended.